Director/PDMR Shareholding

RNS Number : 6138X

Oxford Biomedica PLC

13 August 2018

 

PDMR Dealings / Market Share Sale

Oxford, UK - 13 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 09 August 2018 James Miskin, Chief Technical Officer, exercised 11,759 options at 50p, exercised 500 options at 287.5p and 814 options at 141.5p and sold all of the resulting shares at 904.416p. 

Following this transaction he holds 163,272 options and no shares in the company.

The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	James Miskin
2.	Reason for the notification
a)	Position/status	Chief Technical Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Exercise of options
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £0.500 11,759 £2.875      500 £1.415      814
e)	Aggregated information -   Aggregate volume -   Price -   Aggregated total	13,073 £0.648 £8,468.81
f)	Date of the transaction	2018-08-09
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	James Miskin
2.	Reason for the notification
a)	Position/status	Chief Business Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Disposal
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £9.04416 13,073
e)	Aggregated information -   Aggregate volume -   Price -   Aggregated total	13,073 £9.04416 £118,234.30
f)	Date of the transaction	2018-08-09
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson,  Chief Executive Officer Stuart Paynter, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

DSHGCGDIGUBBGIX